Up to 8-year follow-up from RESONATE-2 : first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
Barr, Paul M. (Clinical Trials Office. Wilmot Cancer Institute. University of Rochester Medical Center)
Owen, Carolyn (Division of Hematology & Hematological Malignancies. Tom Baker Cancer Centre. University of Calgary)
Robak, Tadeusz (Medical University of Lodz)
Tedeschi, Alessandra (Department of Hematology. Azienda Socio Sanitaria Territoriali Grande Ospedale Metropolitano Niguarda)
Bairey, Osnat (Department of Hematology. Rabin Medical Center)
Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center)
Hillmen, Peter (Department of Haematology. The Leeds Teaching Hospitals. St. James Institute of Oncology)
Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Cente)
Dearden, Claire (Haemato-Oncology Department. The Royal Marsden Hospital)
Grosicki, Sebastian (Department of Hematology and Cancer Prevention. School of Public Health. Silesian Medical University)
McCarthy, Helen (Royal Bournemouth General Hospital. Haematology Department)
Li, Jian-Yong (Jiangsu Province Hospital. Department of Hematology)
Offner, Fritz (Universitair Ziekenhuis Gent. Department of Clinical Hematology)
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau)
Zhou, Ccathy (Biostatistics. Pharmacyclics LLC. An AbbVie Company)
Hsu, Emily (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company)
Szoke, Anita (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company)
Kipps, Thomas J. (University of California San Diego. Department of Medicine. Moores Cancer Center)
Ghia, Paolo (Università Vita-Salute San Raffaele. Department of Onco-Hematology. Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele)
Universitat Autònoma de Barcelona

Date:	2022
Note:	Altres ajuts: AstraZeneca; TG Therapeutics; Acerta; Janssen.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Blood advances, Vol. 6 Núm. 11 (june 2022) , p. 3440-3450, ISSN 2473-9537

DOI: 10.1182/bloodadvances.2021006434
PMID: 35377947

11 p, 1.4 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles